Retatrutide

Retatrutide is a first-of-its-class triple receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, enabling enhanced therapeutic outcomes for obesity and type 2 diabetes.¹ In clinical trials, the medication demonstrated superior weight loss efficacy compared to existing pharmacotherapies, with participants receiving the highest doses achieving average reductions of 24.2% to 28.7% of body weight over 48 to 68 weeks.²,³,⁴ Beyond weight reduction, retatrutide improves glycemic control by lowering fasting glucose and HbA1c levels, with some patients achieving normoglycemia, while also enhancing insulin sensitivity and reducing fasting serum insulin concentrations.¹,³,⁵ The drug provides significant metabolic and cardiovascular benefits, including reductions in blood pressure, total cholesterol, and lipid profile improvements, as well as substantial decreases in liver fat accumulation—with up to 82.4% relative reduction in hepatic steatosis at the highest doses.⁵ Additionally, early evidence suggests retatrutide preserves lean body mass more effectively than prior GLP-1 medications, and Phase 2 and 3 trials documented favorable tolerability alongside clinically meaningful improvements in cardiometabolic markers.³,⁵,⁶

The most common side effects of retatrutide are gastrointestinal, including nausea (up to 60% at 12 mg dose), diarrhea (15-33%), vomiting (21-26%), and constipation (11-16%), which are typically mild to moderate, dose-dependent, and most prominent during dose escalation.⁷,⁸ Dysesthesia, such as tingling or altered skin sensation, affects up to 20.9% at 12 mg and is linked to glucagon receptor activity, distinguishing it from other agents.⁷,⁸ Less frequent effects include decreased appetite, injection site reactions (up to 8%), headache, and increased heart rate (5-10 bpm).⁷,⁹ Rare serious risks encompass pancreatitis (0.4%), gallbladder issues (1.1%), hypersensitivity reactions, and heart rhythm changes, with class-wide warnings for thyroid C-cell tumors in patients with relevant history.⁸,⁹,¹⁰ Safety considerations emphasize gradual dose escalation to improve tolerability, monitoring for severe abdominal pain or dehydration, and avoiding use in those with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.⁷,⁸,¹⁰

Retatrutide acts as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, binding to these G-protein-coupled receptors to induce conformational changes that activate adenylate cyclase and elevate intracellular cyclic AMP (cAMP) levels.¹¹,¹²,¹³ This signaling cascade activates protein kinase A and downstream effectors, enhancing glucose-stimulated insulin secretion from pancreatic beta cells while suppressing glucagon release, thereby improving glycemic control.¹,¹¹,¹² Activation of GLP-1 and GIP receptors in the central nervous system and periphery reduces appetite, promotes satiety, slows gastric emptying, and increases glucose uptake, whereas glucagon receptor agonism boosts energy expenditure, lipolysis, and lipid metabolism in the liver and adipose tissue.¹¹,¹²,¹³ Retatrutide exhibits highest potency at the GIP receptor (approximately 8.9-fold greater than native GIP), with moderated activity at GLP-1 and glucagon receptors, supported by a C20 fatty diacid moiety for albumin binding and a ~6-day half-life enabling once-weekly dosing.¹,¹¹